INTRODUCTION
During treatment of cancer, some side effects of conventional treatment may limit the ability of the patient to receive the full course of therapy. To reduce the side effects and improve the effectiveness of standard therapy, many complementary or alternative medicines (CAM) have been tried in patient with a variety of cancers.
Mistletoe extracts are among commonly prescribed CAM for cancer patients. Mistletoe is a semiparasitic plant that grows on several types of trees, including apple, oak, maple, elm, pine, and birch. Viscum album L. extract (VAE) was The immunologic parameters such as interleukin-2 (IL-2), IL-4, IL-6, IL-10, transforming growth factor-beta (TGF-b), and interferon-gamma (IFN-g ) were measured in test group with VAE treatment and in control group.
METHODS

Patients and controls
All patients enrolled in this study were diagnosed with Purpose: To reduce the side effects and improve the effectiveness of standard chemoradiation therapy, many complementary or alternative medicines have been tried. However, little is known about its immunologic effects in breast cancer patients. The aim of this study was to assess the immunologic effects of mistletoe extract (Viscum album L., VAE) in patients with early breast cancer after surgery followed by standard adjuvant chemoradiation therapy. Methods: A total 20 patients with early breast cancer treated with breast conserving surgery followed conventional chemoradiation therapy. Ten of these patients received subcutaneous injections of VAE for 7 weeks. IL-2, IL-4, IL-6, IL-10, TGF-b, and IFN-g levels in serum samples were measured in all patients. Results: The concentrations of IL-2, IL-4, IL-10, and TGF-b were not significantly changed between before and after VAE treatment in both test and control group. The concentration of IL-6 in the test group was increased from 8.19± ±1.75 pg/mL to 9.86± ±1.46 pg/mL after treatment (p=0.013). The concentration of IFN-g in the test group was remarkably increased from 91.76± ±17.16 pg/mL to 167.42± ±66.61 pg/mL after treatment (p=0.009). Conclusion: Significant increases in the concentration of IL-6 and IFN-g were observed after VAE treatment. These results suggest that VAE treatment can stimulate immune responses, especially cell-mediated immunity in immune-compromised patients received the chemoradiation for breast cancer. 
RESULTS
Patients' characteristics
All patients were diagnosed as an invasive ductal carcinoma of breast. One patient of test group had a lobular carcinoma component. The mean age at diagnosis was 46.9 yr, range from 33 to 53 yr in test group and 48.7 yr, range from 41 to 63 yr in control group. Seven patients were stage I and three patients were stage II in each group. Estrogen receptor was positive in six patients in each group (Table 2) .
Cytokines results
The mean concentrations of IL-2 were changed from Figure   2 ). The change in concentration of IFN-g after treatment was statistically significant between test group and control group (p=0.002) ( Table 3) . The results of this study showed the increases of IL-6
and IFN-g levels in peripheral blood by VAE. This suggests that VAE can be used as an immunomodulator in adjuvant setting in patients with breast cancer. However, because this study was carried out on a small numbers of patients, it needs to be confirmed by further studies with a large scale. To more popular use of VAE, further studies for finding out the mechanisms by which VAE increases the immunity will be needed.
CONCLUSION
Significant increases in the serum concentration of IL-6 and IFN-g were observed after VAE treatment. These results suggest that VAE can stimulate immune responses, especially cell-mediated immunity, in immune-compromised patients received the conventional chemoradiation for breast cancer.
